ANL 31.47 Increased By ▲ 0.79 (2.57%)
ASC 14.10 Decreased By ▼ -0.84 (-5.62%)
ASL 23.80 Decreased By ▼ -0.10 (-0.42%)
AVN 94.75 Increased By ▲ 2.75 (2.99%)
BOP 9.14 No Change ▼ 0.00 (0%)
BYCO 9.78 Decreased By ▼ -0.47 (-4.59%)
DGKC 134.80 Decreased By ▼ -0.80 (-0.59%)
EPCL 52.25 Increased By ▲ 2.25 (4.5%)
FCCL 24.90 Increased By ▲ 0.28 (1.14%)
FFBL 24.80 Increased By ▲ 0.55 (2.27%)
FFL 15.20 Decreased By ▼ -0.40 (-2.56%)
HASCOL 10.75 Increased By ▲ 0.01 (0.09%)
HUBC 84.80 Decreased By ▼ -0.40 (-0.47%)
HUMNL 7.00 Decreased By ▼ -0.35 (-4.76%)
JSCL 24.94 Increased By ▲ 0.09 (0.36%)
KAPCO 37.40 Decreased By ▼ -0.45 (-1.19%)
KEL 4.08 Decreased By ▼ -0.07 (-1.69%)
LOTCHEM 14.45 Decreased By ▼ -0.33 (-2.23%)
MLCF 46.95 Increased By ▲ 0.35 (0.75%)
PAEL 37.19 Decreased By ▼ -1.06 (-2.77%)
PIBTL 11.68 Decreased By ▼ -0.12 (-1.02%)
POWER 10.22 Decreased By ▼ -0.28 (-2.67%)
PPL 90.65 Increased By ▲ 0.10 (0.11%)
PRL 25.30 Decreased By ▼ -0.80 (-3.07%)
PTC 8.75 Decreased By ▼ -0.20 (-2.23%)
SILK 1.41 Increased By ▲ 0.01 (0.71%)
SNGP 38.50 Increased By ▲ 0.40 (1.05%)
TRG 141.60 Increased By ▲ 0.50 (0.35%)
UNITY 29.75 Decreased By ▼ -1.75 (-5.56%)
WTL 1.54 Decreased By ▼ -0.03 (-1.91%)
BR100 4,912 Decreased By ▼ -23.77 (-0.48%)
BR30 25,332 Decreased By ▼ -71.47 (-0.28%)
KSE100 45,593 Decreased By ▼ -271.59 (-0.59%)
KSE30 19,056 Decreased By ▼ -117.19 (-0.61%)
Pakistan

Chinese healthcare firm offers clinical trials of COVID-19 vaccine in Pakistan

We hope that a successful clinical trial in Pakistan will make it one of the first few countries for the launch of
23 Apr 2020
  • We hope that a successful clinical trial in Pakistan will make it one of the first few countries for the launch of a COVID-19 vaccine, says Sinopharm.

One of the leading medical organizations in China, Sinopharm has claimed to have developed vaccine for the coronavirus and has invited Pakistan’s National Institute of Health for clinical trials.

“Through our representative HealthBee Projects Private Limited, we would like to extend our offer for cooperation on conducting clinical trials of our recently developed inactivated COVID-19 vaccine to the National Institute of Health (NIH) in our brotherly country, Pakistan,” read the letter sent to Major General Prof Dr. Aamir Ikram, Executive Director of National Institute of Health, by the general manager of China Sinopharm International Corp., Li Can.

“We hope that a successful clinical trial in Pakistan will make it one of the first few countries for the launch of a COVID-19 vaccine. The is the mission that Sinopharm has been given by the government,: read the letter.

Talking to local media, Dr. Ikram informed that the public would get the good news within three months if it all goes well, and was hopeful that they would cover all the testing processes in three months period.

The Chinese firm said that it is one of the first organizations to have led the development of a vaccine for the novel coronavirus. A state-owned enterprise, Sinopharm produces more than 80 percent of the mandatory immunization needs of China and played a leading role in fighting the COVID-19 crisis in the country.

Two different experimental coronavirus vaccines were approved for human tests by China last week. A unit of Sinovac Biotech and the Wuhan Institute of Biological Products are developing these compounds.

In March, China gave the green-light for another clinical trial for a vaccine candidate developed by the Academy of Military Medical Sciences and biotech firm CanSino Bio.